drugset / Trial / NCT00738400

Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome

NCT00738400

Phase 4 Completed 150 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a controlled, randomized, multi-center prospective study of vardenafil to determine efficacy on Erectile Dysfunction (ED), tolerability and safety in men with ED and Metabolic Syndrome. This study will explore the rate of patients who do need to switch to the highest dosage based upon the expectation that most men can stay on vardenafil 10 mg PRN (pro re nata)

Timeline

Start
2008-11
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 5 mg
Subject Vardenafil Small molecule 10 mg
Subject Vardenafil Small molecule 20 mg